About Good Returns  |  Advertise  |  Contact Us  |  Terms & Conditions  |  RSS Feeds Other Sites:   tmmonline.nz  |   landlords.co.nz
Last Article Uploaded: Friday, November 24th, 3:16PM
rss
Latest Headlines

AIA expands cancer benefit reach

AIA is offering its cancer treatment benefit as an optional addition to more of its policies.

Monday, August 28th 2017, 6:00AM

The benefit, which funds Medsafe-approved medicines not funded by Pharmac, had previously only been available as an add-on to AIA’s Real Trauma policies.

This has now been expanded to include Real life and total permanent disability policies.

“AIA New Zealand was the first to see a gap in the market for the Cancer Treatment Benefit, which we launched in March this year. Sales to date have been very encouraging,”  David Savidan, AIA New Zealand’s head of marketing and product, said.

“Detecting cancer early, and getting access to the new generation of proven immunotherapy medicines, can greatly improve a person’s chances of surviving cancer.”

A course of one of the new generation of immunotherapy drugs such as Yervoy (for previously-treated or newly-diagnosed advanced melanoma cases) or the advanced prostate cancer drug Provenge, can cost between tens to hundreds of thousands of dollars per patient.

“AIA New Zealand’s cancer treatment benefit gives immediate access to specialists and diagnostic tools, as well as the leading medicines, whether they are publicly-funded or not,” Savidan said.

The benefit provides cover for specialist visits and diagnostic tests for the diagnosis of cancer. If cancer is present, it provides access to both Pharmac and non-Pharmac treatments and the latest cancer immunotherapy medicines, up to $500,000 per year.

Tags: AIA

« Newpark considers being a licensed dealer groupnib grows market share and distribution »

Special Offers

Comments from our readers

No comments yet

Sign In to add your comment

 

print

Printable version  

print

Email to a friend
Strategy Thoughts
News Bites
Latest Comments
Subscribe Now

Cover Notes - Specific news aimed at risk advisers

Previous News

MORE NEWS»

Most Commented On
About Us  |  Advertise  |  Contact Us  |  Terms & Conditions  |  Privacy Policy  |  RSS Feeds  |  Letters  |  Archive  |  Toolbox
 
Site by Web Developer and eyelovedesign.com